• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Patient expectations and experiences of multiple sclerosis interferon ?-1a treatment: a longitudinal, observational study in routine UK clinical practice
【24h】

Patient expectations and experiences of multiple sclerosis interferon ?-1a treatment: a longitudinal, observational study in routine UK clinical practice

机译：多发性硬化症干扰素α-1a治疗的患者期望和经验：英国常规临床实践中的纵向观察性研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Premature discontinuation and poor treatment adherence are problems in chronic conditions, such as multiple sclerosis in which patients must take long-term treatment in order to receive maximum benefit from their medication. The Assessing needs In Multiple Sclerosis (AIMS) study explored factors related to premature treatment discontinuation and patients' experiences of subcutaneous (sc) interferon (IFN) ?-1a treatment in the UK. Methods: A questionnaire-based survey was integrated into the Bupa Home Healthcare patient-support program, which delivers sc IFN ?-1a to patients in their home. Data were collected via patient questionnaires incorporated into routine clinical care and administered upon registration of a new patient by the coordinator, following initial delivery of treatment, prior to each delivery during therapy and at the end of treatment. Univariate and multivariate analyses were performed to identify factors associated with premature discontinuation. Results: Data were collected from 2,390 patients (1,267 new; 1,123 existing) from 59 UK prescribing centers (November 2006–April 2011). Following the first delivery of sc IFN ?-1a, 94% (1,149/1,225) of patients had received training, and 73% (818/1,120) reported that they had no concerns. In total, 24% of new patients discontinued therapy by the end of the study. In the univariate model, none of the candidate variables tested were significant predictors of treatment discontinuation. The strongest predictors of discontinuation in multivariate analyses were lack of information prior to starting treatment and patients feeling unwell on treatment and geographic region (P<0.05 for each variable). Conclusion: This study suggests that patients feeling well on treatment and provision of high-quality information are the main determinants of persistence with sc IFN ?-1a therapy. A package of care that targets these issues should therefore be considered when initiating sc IFN ?-1a therapy.
机译：背景：过早停药和治疗依从性差是慢性病（例如多发性硬化症）中的问题，在多发性硬化症中，患者必须接受长期治疗才能从药物中获得最大收益。评估多发性硬化症的需求（AIMS）研究探索了与英国过早终止治疗以及患者皮下（sc）干扰素（IFN）β-1a治疗的经历有关的因素。方法：将基于问卷的调查纳入了Bupa家庭医疗保健患者支持计划，该计划向家中的患者提供sc IFNβ-1a。通过纳入常规临床护理的患者调查表收集数据，并由协调员在新患者登记后，首次治疗后，治疗期间每次分娩之前和治疗结束时进行管理。进行单因素和多因素分析以鉴定与过早停药有关的因素。结果：数据来自英国59个处方中心（2006年11月至2011年4月）的2390名患者（新患者1267名;现有1123名）。首次递送sc IFNβ-1a后，有94％（1,149 / 1,225）的患者接受了培训，而73％（818 / 1,120）的患者表示他们没有任何担忧。到研究结束时，总共有24％的新患者中止了治疗。在单变量模型中，测试的所有候选变量都不是治疗中断的重要预测指标。多变量分析中最强的终止预测因素是开始治疗前缺乏信息以及患者在治疗和地理区域上感觉不适（每个变量的P <0.05）。结论：这项研究表明，患者对治疗的感觉良好并提供高质量的信息是sc IFNβ-1a治疗能否持久的主要决定因素。因此，在开始sc IFNβ-1a治疗时应考虑针对这些问题的一揽子护理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号